|Articles|November 17, 2022
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells (Nov 2022)
Author(s)Univercells Technologies
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
2
Charles River Incubator Cohort to Accelerate CGT Development
3
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
4
Developing Next-Gen Cell Lines Using Targeted Integration
5
